DnB Asset Management
FDMT icon

DnB Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

DnB Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,123
Closed -$121K – 1243
2025
Q4 		$121K Sell
16,123
-5,516
-25% -$56K ﹤0.01% 725
2025
Q3 		$188K Sell
21,639
-6,115
-22% -$36.5K ﹤0.01% 720
2025
Q2 		$103K Sell
27,754
-102
-0.4% -$359 ﹤0.01% 709
2025
Q1 		$90K Buy
27,856
+11,558
+71% +$54.5K ﹤0.01% 722
2024
Q4 		$90.8K Sell
16,298
-9,390
-37% -$73.7K ﹤0.01% 722
2024
Q3 		$278K Buy
+25,688
New +$426K ﹤0.01% 682
2024
Q2 		– Sell
-7,363
Closed -$234K – 714
2024
Q1 		$234K Buy
+7,363
New +$188K ﹤0.01% 688

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DnB Asset Management's FDMT Position: Q1 2026 in Review

DnB Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 16,123 shares — an estimated $121K sold.

DnB Asset Management first reported a position in FDMT in Q1 2024 and held it in 7 quarters. The position peaked at $278K in Q3 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • DnB Asset Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DnB Asset Management sold 16,123 4D Molecular Therapeutics shares in Q1 2026, an estimated $121K.
  • DnB Asset Management first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 7 quarters.
  • DnB Asset Management's 4D Molecular Therapeutics position peaked at $278K in Q3 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.